Integrating Newer Therapies in the Treatment of Advanced CTCL: Mycosis Fungoides and Sézary Syndrome

The presentation discusses the integration of newer therapies for advanced cutaneous T-cell lymphoma (CTCL) including Mycosis Fungoides (MF) and Sézary Syndrome. The challenges in managing advanced CTCL stem from its heterogeneity, differing behavior across disease compartments, and the variable effectiveness of therapies. The speaker emphasizes the importance of personalizing treatment strategies based on the patient’s clinical profile, including the presence of large cell transformation and other prognostic factors. Current therapies often rely on single-agent treatments rather than combinations, particularly when bridging to transplant. Analyzing clinical cases reveals how specific therapies can be matched to disease characteristics. For example, mogamulizumab is effective for high-burden leukemic disease, while brentuximab is preferred for patients with large cell transformation and tumor disease. The discussion also highlights the potential of emerging biomarkers and molecular profiling techniques to guide therapy choices, advocating for a more data-driven approach in clinical decision-making. With advancements in cell therapies and genetic profiling, the presentation suggests a forward-looking approach to optimize treatment efficacy while minimizing toxicity, aiming for tailored therapies in this complex and evolving disease landscape.